Mineralys Therapeutics Statistics
Total Valuation
MLYS has a market cap or net worth of $2.35 billion. The enterprise value is $1.71 billion.
| Market Cap | 2.35B |
| Enterprise Value | 1.71B |
Important Dates
The next estimated earnings date is Tuesday, August 11, 2026, after market close.
| Earnings Date | Aug 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
MLYS has 88.16 million shares outstanding. The number of shares has increased by 48.35% in one year.
| Current Share Class | 88.16M |
| Shares Outstanding | 88.16M |
| Shares Change (YoY) | +48.35% |
| Shares Change (QoQ) | +2.84% |
| Owned by Insiders (%) | 0.75% |
| Owned by Institutions (%) | 82.56% |
| Float | 66.03M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 882.02 |
| PB Ratio | 3.45 |
| P/TBV Ratio | 3.69 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 44.33
| Current Ratio | 44.33 |
| Quick Ratio | 43.90 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -30.98% and return on invested capital (ROIC) is -21.88%.
| Return on Equity (ROE) | -30.98% |
| Return on Assets (ROA) | -21.27% |
| Return on Invested Capital (ROIC) | -21.88% |
| Return on Capital Employed (ROCE) | -26.87% |
| Weighted Average Cost of Capital (WACC) | 7.36% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.00M |
| Employee Count | 76 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +87.36% in the last 52 weeks. The beta is 0.56, so MLYS's price volatility has been lower than the market average.
| Beta (5Y) | 0.56 |
| 52-Week Price Change | +87.36% |
| 50-Day Moving Average | 27.42 |
| 200-Day Moving Average | 32.88 |
| Relative Strength Index (RSI) | 53.21 |
| Average Volume (20 Days) | 2,320,254 |
Short Selling Information
The latest short interest is 9.48 million, so 10.75% of the outstanding shares have been sold short.
| Short Interest | 9.48M |
| Short Previous Month | 9.02M |
| Short % of Shares Out | 10.75% |
| Short % of Float | 14.35% |
| Short Ratio (days to cover) | 4.41 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -171.50M |
| Pretax Income | -151.78M |
| Net Income | -151.78M |
| EBITDA | -171.45M |
| EBIT | -171.50M |
| Earnings Per Share (EPS) | -$2.02 |
Balance Sheet
The company has $646.06 million in cash and n/a in debt, with a net cash position of $646.06 million or $7.33 per share.
| Cash & Cash Equivalents | 646.06M |
| Total Debt | n/a |
| Net Cash | 646.06M |
| Net Cash Per Share | $7.33 |
| Equity (Book Value) | 638.14M |
| Book Value Per Share | 7.74 |
| Working Capital | 637.75M |
Cash Flow
In the last 12 months, operating cash flow was -$136.40 million and capital expenditures -$15,000, giving a free cash flow of -$136.42 million.
| Operating Cash Flow | -136.40M |
| Capital Expenditures | -15,000 |
| Depreciation & Amortization | 50,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -136.42M |
| FCF Per Share | -$1.55 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
MLYS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -48.35% |
| Shareholder Yield | -48.35% |
| Earnings Yield | -6.45% |
| FCF Yield | -5.80% |
Analyst Forecast
The average price target for MLYS is $49.00, which is 83.66% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $49.00 |
| Price Target Difference | 83.66% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |